Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on hepatic fibrosis.

about

Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on hepatic fibrosis.

Item

http://www.wikidata.org/entity/Q52688162

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Effect of combined farnesoid X ...... r blocker on hepatic fibrosis.

@en

Effect of combined farnesoid X ...... r blocker on hepatic fibrosis.

@nl

type

Item

label

Effect of combined farnesoid X ...... r blocker on hepatic fibrosis.

@en

Effect of combined farnesoid X ...... r blocker on hepatic fibrosis.

@nl

prefLabel

Effect of combined farnesoid X ...... r blocker on hepatic fibrosis.

@en

Effect of combined farnesoid X ...... r blocker on hepatic fibrosis.

@nl

P1476

Effect of combined farnesoid X ...... r blocker on hepatic fibrosis.

@en

P2093

Daisuke Kaya

http://www.w3.org/2001/XMLSchema#string

Hideto Kawaratani

http://www.w3.org/2001/XMLSchema#string

Hiroaki Takaya

http://www.w3.org/2001/XMLSchema#string

Hitoshi Yoshiji

http://www.w3.org/2001/XMLSchema#string

Kei Moriya

http://www.w3.org/2001/XMLSchema#string

Keisuke Nakanishi

http://www.w3.org/2001/XMLSchema#string

Kenichiro Seki

http://www.w3.org/2001/XMLSchema#string

Kiyoshi Asada

http://www.w3.org/2001/XMLSchema#string

Koh Kitagawa

http://www.w3.org/2001/XMLSchema#string

Kosuke Kaji

http://www.w3.org/2001/XMLSchema#string

P2860

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

Current efforts and trends in the treatment of NASH

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis

Reduction of endotoxin attenuates liver fibrosis through suppression of hepatic stellate cell activation and remission of intestinal permeability in a rat non-alcoholic steatohepatitis model.

Angiotensin-I-converting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor.

Angiotensin-I converting enzyme inhibitors as potential anti-angiogenic agents for cancer therapy.

Lipopolysaccharide Regulation of Intestinal Tight Junction Permeability Is Mediated by TLR4 Signal Transduction Pathway Activation of FAK and MyD88.

Lipopolysaccharide causes an increase in intestinal tight junction permeability in vitro and in vivo by inducing enterocyte membrane expression and localization of TLR-4 and CD14

Crosstalk between angiogenesis, cytokeratin-18, and insulin resistance in the progression of non-alcoholic steatohepatitis.

P304

928-945

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP4.1104

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-09-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29404501

http://www.w3.org/2001/XMLSchema#string

P932

5721465

http://www.w3.org/2001/XMLSchema#string